COVID test

Meet Me in 5: A cross-organizational team delivers a COVID-19 study in record time

Our “Meet Me in 5” series covers 5 people, topics or questions to illustrate how our business nurtures exceptional people, provides an energizing purpose and enables extraordinary potential in its employees’ careers. Every day counts in the fight against the COVID-19 pandemic. That’s why Covance, LabCorp’s drug development business, was …

blog patient intel

Clinical oversight during the COVID-19 pandemic: 5 reporting lessons learned

Clinical trial sponsors need the ability to monitor the health of their study or portfolio of studies on an ongoing basis.  In times of crises, this becomes a challenging task, as the rapidly evolving situation might render standard reporting tools inadequate and outdated. The Xcellerate® technology suite has been developed …

covancecrop1

Using LC-MS/MS to optimize the OECD 456 H295R steroidogenesis assay for sensitive and selective detection

Assessing in vitro steroidogenesis endpoints is an important early step in establishing the endocrine disruptor (ED) potential of your crop protection product. Many regulators worldwide now require this information as part of the registration and approval process; for example, in the E.U., the updated pesticide and biocide directives now requests …

Nurse with swab

Exploring Decentralized Clinical Trials (DCTs) – a new monthly blog series

Welcome to the Covance Decentralized Clinical Trials (DCTs) monthly blog.  With patient-centric trial designs becoming a driving force in the drug development industry, we will be doing a series of monthly blogs that look back on recent events which give us insight into designing resilient clinical trials and ensuring study …

DCT Blog post

Understanding vendor management challenges in Decentralized Clinical Trials (DCT, aka Hybrid and Virtual Trials)

The purported benefits of decentralized clinical trials (DCT) include accelerated enrollment, reduced patient burden and improved retention rates, among other efficiencies. Incorporating virtual elements into the traditional trial model requires a clear vision for the technologies, platforms and other “site-less” elements that support these efforts; however, the potential challenges of …

Using acute respiratory disease syndrome (ARDS) in vivo models to screen for coronavirus inflammation treatment

Solutions to the current COVID-19 pandemic involve preventing coronavirus infection through vaccination and treating the severe clinical symptoms of the disease, including acute respiratory distress syndrome (ARDS). Establishing in vitro screening for potential treatments, though, can be challenging, due to the limited number of appropriate research models available, and the …